Compare Amgen, Inc. (AMGN) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Schlumberger NV — how do they compare? Amgen, Inc. trades at $417.18 (market cap $224.14B), while Schlumberger NV trades at $52.94 (market cap $79.67B). The key difference: Amgen, Inc. is far larger — about 2.8× Schlumberger NV's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | SLB | |
|---|---|---|
Market Cap | $224.14B | $79.67B |
Sector | Health | Energy |
52-Week High | $417.20 | $58.01 |
52-Week Low | $271.18 | $31.72 |
Enterprise Value | $267.45B | $88.40B |
Dividend Yield | 2.43% | 2.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
SLB (NYSE: SLB) trades at $53.02, down 0.34% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.55 exceeding expectations. Revenue trends show stability at $35.7B in 2025, though net income margin declined to 8.53%. Analyst consensus remains overwhelmingly positive with 85% buy ratings and a $63 price target representing 19% upside potential.
SLB's outlook is supported by robust digital and production systems growth, though Middle East exposure and net debt pose near-term risks. The stock offers 2.25% dividend yield with recent quarterly payouts of $0.30. While technical indicators show some overbought conditions with RSI at 74, fundamental strength and Wall Street optimism suggest continued upside potential, balanced by geopolitical and margin compression risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
